Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

February 1, 2022

Conditions
Chronic Kidney Disease stage3Contrast-induced Nephropathy
Interventions
DRUG

Isotonic saline

All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.

DRUG

N-acetyl cysteine

all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .

DRUG

Febuxostat 80 MG

All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.

Trial Locations (1)

1181

Ain shams university hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05264584 - Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3 | Biotech Hunter | Biotech Hunter